#oncology #Amivantamab #lazertinib #lungcancer #Janssen #phase3clinicaltrial #MARIPOSAstudy #EGFRmutatedadvancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #Rybrevant #Lazcluze #EuropeanLungCancerCongress #lungcancertreatment #patientoutcomes
pharmatimes.com/news/amivant...
pharmatimes.com/news/amivant...
Amivantamab plus lazertinib shows survival benefit in lung cancer - PharmaTimes
Janssen drug combination extends life expectancy during trial
pharmatimes.com
April 1, 2025 at 9:46 AM